Tyra Biosciences Insider Sold Shares Worth $409,645, According to a Recent SEC Filing
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30
Tyra Biosciences Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
FDA Grants IND Clearance For Tyra Biosciences' TYRA-300
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
Express News | Tyra Biosciences Receives Ind Clearance From FDA to Proceed With Phase 2 Study of Tyra-300 in Non-Muscle Invasive Bladder Cancer (Surf302)
